The New Market Access Playbook – Webinar with Access Forum

MFN pricing, TrumpRx, and Section 232 tariffs are rewriting the economics of US market access in real time, forcing companies into increasingly fraught choices about how to develop and launch medicines at home and abroad in a way that sustains innovation. At the same time, China’s biopharma sector is closing the innovation gap from the outside, creating both near-term and long-term access challenges.